Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Warnings rise for U.S. as severe flu strain causes outbreaks in Canada, U.K. - 2Shipping: The Corridors of Trade and the Coming of Another Period
- 3Environmental groups urge Germany to cut oil and gas dependence
- 4Last Christmas, 3 million viewers watched a Chiefs love story — will Bills fans fall just as hard this year?
- 5A Time of Careful Eating: Individual Tests in Nourishment
- IDF strikes Tehran command centers, weapon production sites
- Hilary Duff announces new album ‘Luck… or Something,’ her first in over 10 years: ‘Excited is the largest understatement’
- 'Israel has the right to continue its attacks,' Lebanese Foreign Minister announces
- Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warns
- Australians told to continue Easter travel plans despite fuel shortages
- Cameroon says Russia has confirmed 16 Cameroonian soldiers died in Ukraine
- Hamas Navy head, engineer of Khan Yunis tunnel network killed in Gaza, IDF confirms
- Investigating Free Cell Phones: What You Really want to Be aware
- Smuggler who called migrants 'chickens' jailed
